Pathos develops an AI-enabled drug discovery platform that utilizes real-world oncology data and patient-derived functional genomic data to enhance patient selection and biomarker development. The platform aims to expedite the drug development process for biopharmaceutical companies by identifying promising therapeutic candidates that address significant unmet medical needs.
Funding
$365M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug development faces challenges in patient selection and biomarker identification, often leading to inefficient clinical trials and delayed access to effective therapies for patients with significant unmet medical needs. Existing methods may fail to detect compelling biological insights from real-world oncology data and patient-derived functional genomic data.
Solution
Pathos offers an AI-enabled drug discovery platform that leverages real-world oncology data and patient-derived functional genomic data to enhance patient selection and biomarker development. The PathOS Platform™ identifies and validates previously undetected biological insights, optimizing patient selection strategies for clinical trials. By partnering with biopharmaceutical companies, Pathos aims to accelerate the development of precision medicines and improve patient outcomes. The platform focuses on licensing or co-developing clinical-stage therapeutics, ensuring that highly efficacious drugs are developed for the patients most likely to benefit.
Target Audience
The primary customers are biopharmaceutical companies seeking to enhance their drug development process through AI-driven insights and optimized patient selection strategies.
Features
- AI-driven analysis of petabytes of real-world oncology data and patient-derived functional genomic data
- Identification and validation of novel biological insights for drug development
- Optimization of patient selection strategies for clinical trials
- Biomarker development to ensure highly efficacious drugs are developed for the patients most likely to benefit
- Accelerated development paths for faster approval and improved patient outcomes